Discounted Cash Flow (DCF) Analysis Levered

Altimmune, Inc. (ALT)

$13.23

-0.68 (-4.89%)
All numbers are in Millions, Currency in USD
Stock DCF: 7.42 | 13.23 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 10.7410.335.808.19000000
Revenue (%)
Operating Cash Flow -20.21-9.39-9.60-34.44-0.01-0.01-0.01-0-0-0
Operating Cash Flow (%)
Capital Expenditure -0.17-1.02-0.03-0.34-0-0-0-0-0-0
Capital Expenditure (%)
Free Cash Flow -20.38-10.40-9.63-34.78-0.01-0.01-0.01-0-0-0

Weighted Average Cost Of Capital

Share price $ 13.23
Beta 0.190
Diluted Shares Outstanding 25.64
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.415
Total Debt -
Total Equity 339.18
Total Capital 339.18
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 10.7410.335.808.19000000
Operating Cash Flow -20.21-9.39-9.60-34.44-0.01-0.01-0.01-0-0-0
Capital Expenditure -0.17-1.02-0.03-0.34-0-0-0-0-0-0
Free Cash Flow -20.38-10.40-9.63-34.78-0.01-0.01-0.01-0-0-0
WACC
PV LFCF -0.01-0-0-0-0
SUM PV LFCF -0.02

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.42
Free cash flow (t + 1) -0
Terminal Value -0.09
Present Value of Terminal Value -0.07

Intrinsic Value

Enterprise Value -0.09
Net Debt -190.30
Equity Value 190.21
Shares Outstanding 25.64
Equity Value Per Share 7.42